The biotech firm AGC Biologics is closing its services in Boulder and Longmont and is shedding a complete of 267 staff in Colorado beginning Nov. 15.
The corporate stated in a discover to state and native officers Tuesday that it has restructured “in an effort to guard the longevity of the group.” AGC Biologics will completely lay off 218 staff in Boulder, 48 in Longmont and one in Kremmling. Eleven staff in different states who assist the Colorado operations will even be let go.
The positions being eradicated embrace engineers and manufacturing jobs, based on the Employee Readjustment and Retraining Notification Act discover filed with the state.
An AGC spokesperson instructed the commerce publication BioProcess Insider that the restructuring comes as funding in biotech analysis and growth has slowed.
AGC Biologics, a world firm based mostly in Bothell, Wash., has areas in Seattle in addition to Germany, Italy, Japan and Denmark. In 2020, the corporate introduced it had acquired AstraZeneca’s 300,000-square-foot facility in Boulder to revive manufacturing there.
The Colorado Financial Improvement Fee authorised a Job Development Incentive Tax Credit score doubtlessly value $6.4 million and a Strategic Fund incentive of $75,000. Boulder supplied an area match of $75,000. The incentives have been contingent on AGC bringing 280 internet new jobs to Boulder over the following eight years.